Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Tuesday, January 06, 2026The US Food and Drug Administration FDA has accepted for priority review the supplemental biologic license application sBLA for Tzield teplizumabmzwv to expand the current age indication from eight years and above
Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)
Tuesday, January 06, 2026GSK plc today announced that Chinas National Medical Products Administration NMPA has approved Nucala mepolizumab as addon maintenance treatment of adult patients with inadequately controlled COPD characterised by raised blood eosinophils
Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
Wednesday, December 24, 2025Bioeq AG Bioeq a Swiss biopharmaceutical company and Zydus Lifesciences Limited Zydus an innovationled lifesciences company with an international presence today announced that its wholly owned subsidiary
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Tuesday, December 23, 2025Samsung Biologics a leading contract development and manufacturing organization CDMO today announced that its wholly owned US subsidiary Samsung Biologics America has entered into a definitive agreement to acquire
Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv
Tuesday, December 23, 2025Orexo AB announces the signing of an agreement with Dexcel Pharma USA to divest the full rights to Zubsolv buprenorphinenaloxone sublingual tablet CIII for the treatment of opioid use disorder in the US
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
Monday, December 22, 2025Roche announced today that the US Food and Drug Administration FDA has approved CDxCD bispecific Lunsumio VELO mosunetuzumab as a subcutaneous SC formulation for the treatment of adult patients with relapsed
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery
Friday, December 19, 2025Revvity Inctoday announced the introduction of its forthcoming Signals Xynthetica Modelsasa Service MaaS AI offering within the Revvity Signals platform The Signals Xynthetica offering will enable AIaugmented
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care
Friday, December 19, 2025Thermo Fisher Scientific Inc the world leader in serving science today announced the enrollment of the first patient in the new PPD CorEvitas Alzheimers Disease Registry Designed as an international
Peptinovo Biopharma in Collaboration with Chemelectiva Announces Breakthrough Manufacturing Innovation for Targeted Chemotherapy
Thursday, December 18, 2025Peptinovo Biopharma an Ann Arborbased biotechnology company pioneering targeted cancer therapies through its proprietary PALM nanotechnology today announced a major manufacturing and intellectual property milestone
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Wednesday, December 17, 2025Vir Biotechnology Inc today announced that the Company has granted Norgine Pharma UK Limited an affiliate of Norgine a leading European specialty pharmaceutical company an exclusive license for the commercial rights
